Last updated: February 19, 2026
This report details the patent landscape surrounding Australian patent AU2015204192, focusing on its claims, scope, and potential market implications within the pharmaceutical sector. The patent, assigned to CSL Limited, concerns novel polypeptide sequences and their therapeutic applications, primarily targeting viral infections.
What is the Core Innovation of AU2015204192?
The patent AU2015204192 protects a novel polypeptide sequence and its use in treating viral infections. The invention provides isolated polypeptide sequences comprising specific amino acid sequences, along with pharmaceutical compositions containing these polypeptides. The primary therapeutic application described is the inhibition of viral entry into host cells.
What are the Key Claims of AU2015204192?
The patent's claims define the exclusive rights granted to the patent holder. Key claims within AU2015204192 focus on:
- Claim 1: An isolated polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 1. This claim is foundational, defining the specific molecular entity.
- Claim 2: The polypeptide of claim 1, wherein the polypeptide is a fusion protein further comprising a heterologous amino acid sequence. This expands the scope to modified versions of the core polypeptide.
- Claim 3: A pharmaceutical composition comprising the polypeptide of claim 1 or claim 2 and a pharmaceutically acceptable carrier. This claim covers formulations suitable for therapeutic administration.
- Claim 4: A method of treating a viral infection in a subject, comprising administering to the subject an effective amount of the polypeptide of claim 1 or claim 2, or the pharmaceutical composition of claim 3. This claim defines the therapeutic use of the patented invention.
- Claim 5: The method of claim 4, wherein the viral infection is caused by a virus from the Paramyxoviridae family. This narrows the scope to a specific class of viruses, including those causing measles and mumps.
- Claim 6: The method of claim 4, wherein the viral infection is influenza. This further specifies a prominent viral target.
- Claim 7: The method of claim 4, wherein the viral infection is caused by a virus from the Orthomyxoviridae family. This reiterates and broadens the scope to include influenza viruses.
- Claim 8: The method of claim 4, wherein the viral infection is caused by a virus from the Filoviridae family. This includes viruses like Ebola.
- Claim 9: The method of claim 4, wherein the viral infection is caused by a virus from the Coronaviridae family. This encompasses coronaviruses, including SARS-CoV-2.
- Claim 10: The method of claim 4, wherein the viral infection is caused by a virus from the Arenaviridae family. This includes viruses like Lassa fever.
- Claim 11: The method of claim 4, wherein the viral infection is caused by a virus from the Bunyaviridae family.
- Claim 12: The method of claim 4, wherein the viral infection is caused by a virus from the Rhabdoviridae family.
- Claim 13: The method of claim 4, wherein the viral infection is caused by a virus from the Picornaviridae family.
- Claim 14: The method of claim 4, wherein the viral infection is caused by a virus from the Flaviviridae family.
- Claim 15: The method of claim 4, wherein the viral infection is caused by a virus from the Hepadnaviridae family.
- Claim 16: The method of claim 4, wherein the viral infection is caused by a virus from the Retroviridae family.
- Claim 17: The method of claim 4, wherein the viral infection is caused by a virus from the Herpesviridae family.
- Claim 18: The method of claim 4, wherein the viral infection is caused by a virus from the Poxviridae family.
- Claim 19: The method of claim 4, wherein the viral infection is caused by a virus from the Reoviridae family.
- Claim 20: The method of claim 4, wherein the viral infection is caused by a virus from the Caliciviridae family.
- Claim 21: The method of claim 4, wherein the viral infection is caused by a virus from the Hantavirus genus.
The breadth of viral families covered in the method claims is significant, suggesting a broad therapeutic potential if the polypeptide proves effective against a wide range of pathogens.
What is the Scope of Protection Afforded by AU2015204192?
The scope of protection is determined by the breadth of the claims and the specific wording used. AU2015204192 provides protection for:
- The specific polypeptide sequence: Claim 1 is narrow, covering only the defined SEQ ID NO: 1.
- Fusion proteins incorporating the sequence: Claim 2 extends protection to modified versions of the polypeptide, increasing the potential for enforcement against related compounds.
- Pharmaceutical compositions: Claim 3 covers the formulation and delivery of the polypeptide.
- Therapeutic methods: Claims 4 through 21 define the use of the polypeptide in treating a wide array of viral infections. The enumeration of numerous viral families indicates an intent to cover a broad spectrum of viral diseases.
The patent's lifecycle in Australia commenced with its filing date on July 23, 2015, and its grant date was October 26, 2017. Its term is scheduled to expire on July 23, 2035, subject to the payment of renewal fees.
What is the Global Patent Landscape for Similar Innovations?
A review of the global patent landscape reveals that the development of polypeptide-based antiviral therapeutics is an active area of research and patenting. Several entities are pursuing strategies to inhibit viral entry or replication through molecular interventions.
Key Competitors and Their Patenting Strategies
- CSL Limited: As the assignee of AU2015204192, CSL Limited is a primary player in this domain. Their strategy appears to involve defining specific molecular entities and then broadly claiming their therapeutic applications against a wide range of viral pathogens.
- Other Pharmaceutical Companies: Major pharmaceutical companies, including but not limited to Pfizer, GlaxoSmithKline, Moderna, and Gilead Sciences, have filed patents related to antiviral agents, including those targeting viral entry mechanisms. Patent filings from these entities often cover novel small molecules, antibodies, and recombinant proteins designed to interfere with viral life cycles.
- Academic and Research Institutions: Universities and research institutes globally are also active in identifying and patenting novel antiviral compounds and mechanisms. These patents often serve as foundational intellectual property for potential future commercialization by larger entities.
Trends in Antiviral Patenting
- Broad Viral Targets: A significant trend is the pursuit of broad-spectrum antivirals that can combat multiple viral families. This is reflected in the extensive list of viral families claimed in AU2015204192.
- Mechanism-Based Inventions: Patents increasingly focus on specific mechanisms of action, such as inhibiting viral fusion, blocking receptor binding, or interfering with viral RNA/DNA replication.
- Combination Therapies: While not directly addressed by AU2015204192's primary claims, the broader landscape shows increasing patenting around combinations of antiviral agents to enhance efficacy and overcome resistance.
- Delivery and Formulation Innovations: Patents are also being filed for novel delivery systems and formulations that improve the stability, bioavailability, and targeted delivery of antiviral drugs.
What are the Potential Market and R&D Implications for AU2015204192?
The patent AU2015204192 has several implications for the pharmaceutical market and ongoing R&D:
Market Exclusivity
The patent grants CSL Limited market exclusivity for the claimed polypeptide and its use in treating specified viral infections in Australia until July 2035. This exclusivity prevents competitors from manufacturing, using, selling, or importing the patented invention in Australia during this period.
R&D Considerations
- Freedom to Operate: Companies developing antiviral therapies that may target similar mechanisms or viruses would need to conduct thorough freedom-to-operate analyses to avoid infringing AU2015204192. This would involve examining the patent's claims in detail and assessing whether their proposed product or method falls within the scope of the patent.
- Licensing Opportunities: CSL Limited may offer licenses for its patented technology to other entities for specific applications or territories, creating potential revenue streams and facilitating broader access to the therapeutic.
- Targeted Development: For companies developing antivirals against the specific viral families listed in the claims, AU2015204192 represents a significant barrier. Research efforts might need to focus on distinct mechanisms of action or target viruses not covered by the patent.
- Generic Competition Planning: Upon patent expiry in July 2035, generic manufacturers could enter the market with equivalent products, provided no other overlapping patents or regulatory exclusivities are in place.
Therapeutic Area Focus
The patent's broad claims across numerous viral families suggest a strategic focus on developing a versatile antiviral agent. This could have implications for:
- Pandemic Preparedness: A broad-spectrum antiviral could be invaluable in responding to emerging infectious diseases.
- Treatment of Neglected Tropical Diseases: Some of the claimed viral families are associated with diseases prevalent in developing regions.
- Management of Chronic Viral Infections: Depending on the polypeptide's efficacy and safety profile, it could find use in managing long-term viral infections.
The specificSEQ ID NO: 1 polypeptide sequence, its properties, and the resulting clinical data would determine the ultimate commercial viability and therapeutic impact of this patent.
Key Takeaways
- Australian patent AU2015204192, owned by CSL Limited, protects a novel polypeptide (SEQ ID NO: 1) and its therapeutic use against a wide range of viral infections.
- The patent claims cover the specific polypeptide, fusion proteins thereof, pharmaceutical compositions, and methods of treating viral infections, including those caused by Paramyxoviridae, Orthomyxoviridae (influenza), Filoviridae, Coronaviridae, and many other viral families.
- Market exclusivity in Australia for the patented invention extends until July 23, 2035.
- The global patent landscape for antiviral R&D is competitive, with a trend towards broad-spectrum agents and mechanism-based innovations.
- Companies seeking to develop antiviral therapies in Australia must assess freedom to operate relative to AU2015204192, potentially requiring licensing or focusing on distinct therapeutic approaches.
Frequently Asked Questions
-
What specific viral families are explicitly mentioned in the claims of AU2015204192?
The claims enumerate methods of treating infections caused by viruses from the Paramyxoviridae, Orthomyxoviridae, Filoviridae, Coronaviridae, Arenaviridae, Bunyaviridae, Rhabdoviridae, Picornaviridae, Flaviviridae, Hepadnaviridae, Retroviridae, Herpesviridae, Poxviridae, Reoviridae, and Caliciviridae families, as well as the Hantavirus genus.
-
When does patent AU2015204192 expire in Australia?
The patent is scheduled to expire on July 23, 2035, assuming all renewal fees are paid.
-
Does AU2015204192 protect only the specific polypeptide sequence defined by SEQ ID NO: 1?
No, the patent also claims fusion proteins incorporating this sequence and pharmaceutical compositions containing it, in addition to the methods of its therapeutic use.
-
Can other companies develop antiviral treatments targeting influenza viruses in Australia while AU2015204192 is in force?
Development is permissible if their treatment does not infringe upon the specific claims of AU2015204192. This requires careful freedom-to-operate analysis, particularly concerning the method of treating influenza claims and the specific polypeptide or its equivalents.
-
What is the primary mechanism of action described for the polypeptide in AU2015204192?
The patent describes the therapeutic application of the polypeptide as inhibiting viral entry into host cells.
Citations
[1] CSL Limited. (2017). Australian Patent AU2015204192 B2. IP Australia.
[2] CSL Limited. (2015). PCT Application WO2016007024 A1. World Intellectual Property Organization. (While not directly Australian, PCT applications inform the global strategy and prosecution of related national phase patents).
